These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 10347985)

  • 21. Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials Network.
    Keefer MC; Graham BS; Belshe RB; Schwartz D; Corey L; Bolognesi DP; Stablein DM; Montefiori DC; McElrath MJ; Clements ML
    AIDS Res Hum Retroviruses; 1994 Dec; 10(12):1713-23. PubMed ID: 7888231
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of therapeutic intensification followed by HIV DNA prime and rAd5 boost vaccination on HIV-specific immunity and HIV reservoir (EraMune 02): a multicentre randomised clinical trial.
    Achenbach CJ; Assoumou L; Deeks SG; Wilkin TJ; Berzins B; Casazza JP; Lambert-Niclot S; Koup RA; Costagliola D; Calvez V; Katlama C; Autran B; Murphy RL;
    Lancet HIV; 2015 Mar; 2(3):e82-91. PubMed ID: 26424549
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term persistence of vaccination and HAART to human immunodeficiency virus (HIV).
    Boström AC; Hejdeman B; Matsuda R; Fredriksson M; Fredriksson EL; Bratt G; Sandström E; Wahren B
    Vaccine; 2004 Apr; 22(13-14):1683-91. PubMed ID: 15068851
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunisation with gp160 in HIV-1 infection.
    Fiala C; Stewart GT
    Lancet; 1999 Sep; 354(9182):948; author reply 949. PubMed ID: 10489976
    [No Abstract]   [Full Text] [Related]  

  • 25. Phase I clinical trial with HIV-1 gp160 plasmid vaccine in HIV-1-infected asymptomatic subjects.
    Weber R; Bossart W; Cone R; Luethy R; Moelling K
    Eur J Clin Microbiol Infect Dis; 2001 Nov; 20(11):800-3. PubMed ID: 11783696
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160.
    Lee D; Graham BS; Chiu YL; Gilbert PB; McElrath MJ; Belshe RB; Buchbinder SP; Sheppard HW; Koblin BA; Mayer KH; Keefer MC; Mulligan MJ; Celum CL
    J Infect Dis; 2004 Sep; 190(5):903-7. PubMed ID: 15295694
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.
    Pitisuttithum P; Gilbert P; Gurwith M; Heyward W; Martin M; van Griensven F; Hu D; Tappero JW; Choopanya K;
    J Infect Dis; 2006 Dec; 194(12):1661-71. PubMed ID: 17109337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.
    Ensoli B; Nchabeleng M; Ensoli F; Tripiciano A; Bellino S; Picconi O; Sgadari C; Longo O; Tavoschi L; Joffe D; Cafaro A; Francavilla V; Moretti S; Pavone Cossut MR; Collacchi B; Arancio A; Paniccia G; Casabianca A; Magnani M; Buttò S; Levendal E; Ndimande JV; Asia B; Pillay Y; Garaci E; Monini P;
    Retrovirology; 2016 Jun; 13(1):34. PubMed ID: 27277839
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group.
    Cameron DW; Heath-Chiozzi M; Danner S; Cohen C; Kravcik S; Maurath C; Sun E; Henry D; Rode R; Potthoff A; Leonard J
    Lancet; 1998 Feb; 351(9102):543-9. PubMed ID: 9492772
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.
    Buchbinder SP; Mehrotra DV; Duerr A; Fitzgerald DW; Mogg R; Li D; Gilbert PB; Lama JR; Marmor M; Del Rio C; McElrath MJ; Casimiro DR; Gottesdiener KM; Chodakewitz JA; Corey L; Robertson MN;
    Lancet; 2008 Nov; 372(9653):1881-1893. PubMed ID: 19012954
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E.
    Rerks-Ngarm S; Paris RM; Chunsutthiwat S; Premsri N; Namwat C; Bowonwatanuwong C; Li SS; Kaewkungkal J; Trichavaroj R; Churikanont N; de Souza MS; Andrews C; Francis D; Adams E; Flores J; Gurunathan S; Tartaglia J; O'Connell RJ; Eamsila C; Nitayaphan S; Ngauy V; Thongcharoen P; Kunasol P; Michael NL; Robb ML; Gilbert PB; Kim JH
    J Infect Dis; 2013 Apr; 207(8):1195-205. PubMed ID: 22837492
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group.
    Corey L; McElrath MJ; Weinhold K; Matthews T; Stablein D; Graham B; Keefer M; Schwartz D; Gorse G
    J Infect Dis; 1998 Feb; 177(2):301-9. PubMed ID: 9466515
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction of specific T-cell responses in HIV infection.
    Leandersson AC; Bratt G; Hinkula J; Gilljam G; Cochaux P; Samson M; Sandström E; Wahren B
    AIDS; 1998 Jan; 12(2):157-66. PubMed ID: 9468364
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Active anti-interferon-alpha immunization: a European-Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1--infected patients (the EURIS study).
    Gringeri A; Musicco M; Hermans P; Bentwich Z; Cusini M; Bergamasco A; Santagostino E; Burny A; Bizzini B; Zagury D
    J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Apr; 20(4):358-70. PubMed ID: 10096580
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human immunodeficiency virus (HIV-1) gp160-specific lymphocyte proliferative responses of mononuclear leukocytes from HIV-1 recombinant gp160 vaccine recipients.
    Keefer MC; Bonnez W; Roberts NJ; Dolin R; Reichman RC
    J Infect Dis; 1991 Mar; 163(3):448-53. PubMed ID: 1995718
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term immunotherapy in HIV infection, combined with short-term antiretroviral treatment.
    Bratt G; Eriksson LE; Sandström E; Gilljam G; Hinkula J; Albert J; Redfield R; Wahren B
    Int J STD AIDS; 1999 Aug; 10(8):514-21. PubMed ID: 10471100
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A case for preART-adjusted endpoints in HIV therapeutic vaccine trials.
    Huang Y; Zhang L; Jolliffe D; Hovden AO; Ökvist M; Pantaleo G; Sommerfelt MA
    Vaccine; 2016 Mar; 34(10):1282-8. PubMed ID: 26826543
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study.
    ; Carey D; Puls R; Amin J; Losso M; Phanupak P; Foulkes S; Mohapi L; Crabtree-Ramirez B; Jessen H; Kumar S; Winston A; Lee MP; Belloso W; Cooper DA; Emery S
    Lancet Infect Dis; 2015 Jul; 15(7):793-802. PubMed ID: 25877963
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: a randomised placebo-controlled study.
    Harrer T; Plettenberg A; Arastéh K; Van Lunzen J; Fätkenheuer G; Jaeger H; Janssens M; Burny W; Collard A; Roman F; Loeliger A; Koutsoukos M; Bourguignon P; Lavreys L; Voss G
    Vaccine; 2014 May; 32(22):2657-65. PubMed ID: 24144472
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epitope-specific immunotherapy targeting CD4-positive T cells in coeliac disease: two randomised, double-blind, placebo-controlled phase 1 studies.
    Goel G; King T; Daveson AJ; Andrews JM; Krishnarajah J; Krause R; Brown GJE; Fogel R; Barish CF; Epstein R; Kinney TP; Miner PB; Tye-Din JA; Girardin A; Taavela J; Popp A; Sidney J; Mäki M; Goldstein KE; Griffin PH; Wang S; Dzuris JL; Williams LJ; Sette A; Xavier RJ; Sollid LM; Jabri B; Anderson RP
    Lancet Gastroenterol Hepatol; 2017 Jul; 2(7):479-493. PubMed ID: 28506538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.